Both previous investigations (Jeanson et al. 2019) and our findings in this study have shown that targeting MAPK-ERK pathway with MEK inhibitors can overcome acquired resistance to osimertinib, indicating that trametinib might be an optimal choice for NSCLC patients with osimertinib resistance (Li et al. 2020; Della Corte et al. 2018; Tricker et al. 2015). Here, MAP2K7 is linked to non-small cell lung carcinoma.